Aclaris Therapeutics Stock Net Income
| ACRS Stock | USD 1.22 0.02 1.61% |
Aclaris Therapeutics fundamentals help investors to digest information that contributes to Aclaris Therapeutics' financial success or failures. It also enables traders to predict the movement of Aclaris Stock. The fundamental analysis module provides a way to measure Aclaris Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aclaris Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -88.5 M | -92.9 M | |
| Net Loss | -88.5 M | -92.9 M | |
| Net Loss | -78.2 M | -82.1 M | |
| Net Loss | (1.27) | (1.33) | |
| Net Income Per E B T | 1.00 | 1.19 |
Aclaris | Net Income |
Aclaris Therapeutics Company Net Income Analysis
Aclaris Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Aclaris Therapeutics Net Income | (88.48 M) |
Most of Aclaris Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aclaris Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Aclaris Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Aclaris Therapeutics is extremely important. It helps to project a fair market value of Aclaris Stock properly, considering its historical fundamentals such as Net Income. Since Aclaris Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aclaris Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aclaris Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Aclaris Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Aclaris Therapeutics reported net income of (88.48 Million). This is 125.93% lower than that of the Pharmaceuticals sector and 151.11% lower than that of the Health Care industry. The net income for all United States stocks is 115.5% higher than that of the company.
Aclaris Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aclaris Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aclaris Therapeutics could also be used in its relative valuation, which is a method of valuing Aclaris Therapeutics by comparing valuation metrics of similar companies.Aclaris Therapeutics is currently under evaluation in net income category among related companies.
Aclaris Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aclaris Therapeutics from analyzing Aclaris Therapeutics' financial statements. These drivers represent accounts that assess Aclaris Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aclaris Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 78.1M | 275.2M | 824.9M | 73.3M | 84.3M | 80.1M | |
| Enterprise Value | 42.8M | 232.4M | 798.2M | 33.8M | 38.9M | 37.0M |
Aclaris Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Aclaris Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aclaris Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aclaris Therapeutics' value.| Shares | Gsa Capital Partners Llp | 2023-12-31 | 1.6 M | Two Sigma Investments Llc | 2023-12-31 | 1.5 M | Two Sigma Advisers, Llc | 2023-12-31 | 1.4 M | Geode Capital Management, Llc | 2023-12-31 | 1.4 M | State Street Corporation | 2023-12-31 | 1.4 M | Goldman Sachs Group Inc | 2023-12-31 | 1 M | Vr Adviser, Llc | 2023-09-30 | 1 M | Monaco Asset Management | 2023-12-31 | 979.4 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 975.9 K | Bvf Inc | 2023-09-30 | 7.1 M | Blackrock Inc | 2023-12-31 | 5.9 M |
Aclaris Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.33 | ||||
| Profit Margin | (2.83) % | ||||
| Operating Margin | (1.35) % | ||||
| Current Valuation | (29.08 M) | ||||
| Shares Outstanding | 70.92 M | ||||
| Shares Owned By Insiders | 2.78 % | ||||
| Shares Owned By Institutions | 95.82 % | ||||
| Number Of Shares Shorted | 4.89 M | ||||
| Price To Earning | (12.14) X | ||||
| Price To Book | 0.55 X | ||||
| Price To Sales | 2.75 X | ||||
| Revenue | 31.25 M | ||||
| Gross Profit | (60.02 M) | ||||
| EBITDA | (134.41 M) | ||||
| Net Income | (88.48 M) | ||||
| Cash And Equivalents | 248.6 M | ||||
| Cash Per Share | 3.73 X | ||||
| Total Debt | 426 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.99 X | ||||
| Book Value Per Share | 2.22 X | ||||
| Cash Flow From Operations | (78.33 M) | ||||
| Short Ratio | 4.06 X | ||||
| Earnings Per Share | (1.27) X | ||||
| Price To Earnings To Growth | (0.13) X | ||||
| Target Price | 1.8 | ||||
| Number Of Employees | 86 | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 86.53 M | ||||
| Total Asset | 197.41 M | ||||
| Retained Earnings | (770.8 M) | ||||
| Working Capital | 97.9 M | ||||
| Current Asset | 86.52 M | ||||
| Current Liabilities | 1.55 M | ||||
| Net Asset | 197.41 M |
About Aclaris Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aclaris Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aclaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aclaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Aclaris Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aclaris Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aclaris Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Aclaris Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aclaris Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aclaris Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aclaris Therapeutics to buy it.
The correlation of Aclaris Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aclaris Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aclaris Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aclaris Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Aclaris Therapeutics Piotroski F Score and Aclaris Therapeutics Altman Z Score analysis. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Aclaris Stock analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Aclaris Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 0.448 | Quarterly Revenue Growth 1.266 | Return On Assets (0.33) | Return On Equity (0.50) |
The market value of Aclaris Therapeutics is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapeutics' market value can be influenced by many factors that don't directly affect Aclaris Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.